TREATMENT OUTCOME OF SQUAMOUS CELL CARCINOMA OF THE TONGUE.

Submission of Research Report in the partial fulfillment for a Degree of Master of Clinical Dentistry (Oral and Maxillofacial Surgery).

By,

MOHD NURY BIN YUSOFF, BDS (Malaya).

Supervisor:

Associate Professor Dr. P. Shanmuhasuntharam.

Department of Oral and Maxillofacial Surgery,

Faculty of Dentistry

University of Malaya

Kuala Lumpur

Malaysia.

2007.

ACKNOWLEDGEMENT.

I would like to thanks and acknowledge my supervisor Assoc. Prof. Dr. P. Shanmuhansuntharam, for his continuous support, advices and guidance in my study. He has taught me a lot and given me an impressive input of knowledge throughout the course. I also want to put my appreciation to Department of Record in University Malaya Medical Centre and Dental Faculty and their staffs for allowing me to get access for patients' record in order to make my study happened. To En. Saiful, En. Halim and En. Rosli, your cooperation in helping to get the folders were much appreciated as well as other staff in OMFS Department.

Special thanks to Prof. Dr. Zainal Ariff, the Head of Oral & Maxillofacial Surgery Department and all the lectures for their support, encouragement and made 4 years study in OMFS Department was a great moment in my career. To my beloved wife, Zuriwati Mohamad and my four children; Anis Ameera, Amirul Nazreen, Aleeya Nazifa and Aleesya Sofea and also to my parent, thank you very much for your patience, support and under standing. Your sacrifices were not repayable. To all those inadvertently not singly mentioned thank you for being a part of this study. All sweet memories in this department were unforgettable.

ABSTRACT.

The main aim for this study is to provide clear picture regarding the outcome of tongue cancer patients treated in University Malaya Medical Centre. This centre can be addressed as a Centre of Referral for Malaysia generally. Tongue cancer is a complex disease and it was related to poor outcome even after treatment.

In this retrospective study, 48 patients with squamous cell carcinoma of tongue were identified from record unit. Patient's data collected since January 1992 until December 2005, whereby patients were treated either by Oral & Maxillofacial Department, Dental Faculty, University Malaya or Department of ENT University Malaya Medical Centre.

Of 48 patients, only 30 patients eligible for the study and the remaining have to be excluded due to several reasons. About 43 % of sample was Chinese and followed by Indian, Malays and other races. All the lesion were diagnosed as squamous cell carcinoma and it was involved age of 16 to 74 with age mean 50. The incidence was common in the old patient group (>46) which recorded 63.3% and 36.7% in young patient (< 46). Gender ratio almost equal.

80% of cases were diagnosed as oral tongue cancer and the rest involved base of tongue. 43.3% of patients in stage IV, 30% in stage II and 13.3% in stage I and III. Neck involvement; 53.3% with NO, 13.3% with N1, N2a and N2b another 3.3% with N2c and N3. Histological grading; 56.7% moderately differentiated, 40% well and another 3.3% poorly differentiated.

CONTENT

TITLE PAGE	I
ACKNOWLEDGMENT	II
ABSTRACT	III
CONTENT	V
LIST OF TABLES	VIII
LIST OF FIGURES	X
Chapter 1: INTRODUCTION	1
Chapter 2 : LITERATURE REVIEW	3
2.1. General	3
2.2. Oral cancer in Malaysia	3
2.3. Oral cancer in global	4
2.4. Etiology	6
2.5. Tumour characteristic	7
2.6. Treatment modalities	16
2.7. Neck treatment	20
2.8. Prognosis and survival	24
Chapter 3: PURPOSE OF STUDY	29
3.1. Aim	29
3.2. Objectives	29
Chapter 4: MATERIALS AND METHODS	30
4.1. Materials	30

4.2. Methods	31
4.3. Categorical analysis of data	32
4.4. Criteria of case inclusion	34
4.5. Criteria of case exclusion	34
Chapter 5 : RESULTS	35
5.1. Demographic data	35
5.1.1. Age	35
5.1.2. Gender	36
5.1.3. Ethnic	37
5.1.4. Tumour site	38
5.1.5. Tumour size	39
5.1.6. Neck node	40
5.1.7. Staging	41
5.1.8. Histopathological examination	42
5.1.9. Treatment of primary site	43
5.1.10. Neck treatment	44
5.1.11. Recurrence	45
5.1.12. Status	46
5.2. Survival analysis	48
5.2.1. Overall survival	48
5.2.2. Survival by age	50
5.2.3. Survival by staging	52
5.2.4. Survival by clinical nodes	54

5.2.5. Survival by treatment	56
5.2.6. Survival by subsite	58
5.2.7. Survival by HPE grading	60
5.3. Disease free period	62
5.3.1. Disease free by stage	62
5.3.2. Disease free by HPE grading	63
5.3.3. Disease free by treatment	63
5.3.4. Disease free by site	64
5.4. Disease recurrence	64
5.4.1. Incidence of recurrence	64
5.4.2. Site of recurrences	65
Chapter 6 : DISCUSSION	66
Chapter 7 : CONCLUSION	78
REFERENCES	80
APPENDIX 1	88

For the oral tongue, all the cancers were located at lateral border of tongue except one occurred on dorsum. Presently, surgery, radiotherapy, chemotherapy or combinations are the option treatment modalities for cancer. Patients came to the centre with multi characteristics tumour appearances which determined the mode of treatment. 40% (n=12) and 27% (n=8) of patients underwent surgery and radiotherapy respectively, 26.7% received surgery and post operative radiotherapy, 3.3% had radiotherapy and surgery and 3.3% had other mode of treatment. Neck treatment; 56.7% do not have any neck treatment, 16.7% had radical neck dissection (RND), 16.7% had bilateral neck dissections and 10% had selective neck dissection.

Overall 5 year survival was about 27 %. By site, 5 year survival for oral tongue cancer was 33% and nil for base of tongue. The 5 years survival probability for stage I (75%), stage 2 / stage 3 (33.3%) and 7.7% for stage 4. The 5 years survival probability for N0 (43.8%), N2a (25%) and none for N1, N2b, N2c and N3. Staging of disease and neck node involvement were statistically significant for survival. Patient with early cancer stage (Stage I & II) have a better disease control. About 1/3 (n=11) of samples have more than 2 years disease free period. Recurrence occurred in 43.3% (n=13) of patients and 61.5% of that occurred in the neck region. Out of 30 patients, 26.7% (n=8) of them still alive and most of them from young group patient (< 46).

LIST OF TABLES.

- 1. Table 1: TNM Classification (UICC and AJCC 1988) of tumour size (T)
- 2. Table 2: TNM Classification for regional metastasis (N).
- 3. Table 3: TNM Classification for metastasis (M).
- 4. Table 4 : Staging grouping for oral cancer (UICC 1997)
- 5. Table 5: Histological Grading.
- 6. Table 6 : Patients' mean age & age range
- 7. Table 7: Gender distribution
- 8. Table 8: Ethnic distribution
- 9. Table 9: Site of tumour
- 10. Table 10: Tumour Size
- 11. Table 11: Neck node involvement
- 12. Table 12: Staging
- 13. Table 13: HPE Distribution
- 14. Table 14: Treatment distribution.
- 15. Table 15: Neck Treatment
- 16. Table 16: Incidence of recurrent..
- 17. Table 17: Patient's status.
- 18. Table 18: Overall survival.
- 19. Table 19: Survival by age
- 20. Table 20: Survival by clinical staging
- 21. Table 21: Survival by clinical nodes
- 22. Table 22: 5 year-survival by treatment.

- 23. Table 23: 5 year-survival by cancer sub site.
- 24. Table 24: Survival by HPE grading
- 25. Table 25: 2 years disease free by stage
- 26. Table 26: 2 years disease free period by HPE grading
- 27. Table 27: 2 years disease free period by treatment.
- 28. Table 28: 2 years disease free by site.
- 29. Table 29: Incidence of recurrence
- 30. Table 30: Site of recurrence

LIST OF FIGURES.

- 1. Figure 1. Gender distribution.
- 2. Figure 2: Ethnic distribution.
- 3. Figure 3 : Site Distribution
- 4. Figure 4 : Size (T)
- 5. Figure 5: Neck node distribution
- 6. Figure 6: Staging distribution
- 7. Figure 7: HPE Distribution
- 8. Figure 8: Treatment distribution.
- 9. Figure 9: Neck treatment distribution
- 10. Figure 10: Recurrent distribution
- 11. Figure 11: Patient's status distribution
- 12. Figure 12: Kaplan-Meier curve for overall survival
- 13. Figure 13: Kaplan Meier survival curve by age
- 14. Figure 14: Kaplan Meier survival curve by clinical staging
- 15. Figure 15: Kaplan Meier survival curve by clinical nodes.
- 16. Figure 16: Kaplan Meier Survival curve by treatments.
- 17. Figure 17: Kaplan Meier survival curve by cancer sub site
- 18. Figure 18: Kaplan Meier survival curve by HPE grading.